Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Acute Myocardial Infarction with Mildly Reduced Ejection Fraction
ChiCTR2600119767Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vericiguat in myocardial infarction (MI) and heart failure with mid-range ejection fraction (HFmrEF) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoints: NT-proBNP/BNP levels, Absolute improvement in left ventricular ejection fraction (LVEF) compared to baseline (%) and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
myocardial infarction (MI)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on ChiCTR2600119767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119767.